Abcellera Stock Based Compensation To Revenue from 2010 to 2024
| ABCL Stock | USD 2.81 0.14 4.75% |
Stock Based Compensation To Revenue | First Reported 2010-12-31 | Previous Quarter 1.68791584 | Current Value 1.77 | Quarterly Volatility 0.58372654 |
Check Abcellera Biologics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Abcellera Biologics' main balance sheet or income statement drivers, such as Net Interest Income of 44.4 M, Interest Income of 44.4 M or Depreciation And Amortization of 32.4 M, as well as many indicators such as Price To Sales Ratio of 41.25, Dividend Yield of 0.0 or PTB Ratio of 1.36. Abcellera financial statements analysis is a perfect complement when working with Abcellera Biologics Valuation or Volatility modules.
Abcellera | Stock Based Compensation To Revenue |
Latest Abcellera Biologics' Stock Based Compensation To Revenue Growth Pattern
Below is the plot of the Stock Based Compensation To Revenue of Abcellera Biologics over the last few years. It is a metric that compares the total value of stock-based compensation granted by a company to its total revenue, indicating how much of the revenue is used to compensate employees with stock options or awards. Abcellera Biologics' Stock Based Compensation To Revenue historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Abcellera Biologics' overall financial position and show how it may be relating to other accounts over time.
| Stock Based Compensation To Revenue | 10 Years Trend |
|
Stock Based Compensation To Revenue |
| Timeline |
Abcellera Stock Based Compensation To Revenue Regression Statistics
| Arithmetic Mean | 0.29 | |
| Geometric Mean | 0.11 | |
| Coefficient Of Variation | 199.86 | |
| Mean Deviation | 0.38 | |
| Median | 0.07 | |
| Standard Deviation | 0.58 | |
| Sample Variance | 0.34 | |
| Range | 1.734 | |
| R-Value | 0.59 | |
| Mean Square Error | 0.24 | |
| R-Squared | 0.35 | |
| Significance | 0.02 | |
| Slope | 0.08 | |
| Total Sum of Squares | 4.77 |
Abcellera Stock Based Compensation To Revenue History
About Abcellera Biologics Financial Statements
Abcellera Biologics investors utilize fundamental indicators, such as Stock Based Compensation To Revenue, to predict how Abcellera Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Stock Based Compensation To Revenue | 1.69 | 1.77 |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out the analysis of Abcellera Biologics Correlation against competitors. For more information on how to buy Abcellera Stock please use our How to buy in Abcellera Stock guide.You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Abcellera Biologics. If investors know Abcellera will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Abcellera Biologics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.459 | Earnings Share (0.61) | Revenue Per Share 0.112 | Quarterly Revenue Growth (0.01) | Return On Assets (0.13) |
The market value of Abcellera Biologics is measured differently than its book value, which is the value of Abcellera that is recorded on the company's balance sheet. Investors also form their own opinion of Abcellera Biologics' value that differs from its market value or its book value, called intrinsic value, which is Abcellera Biologics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Abcellera Biologics' market value can be influenced by many factors that don't directly affect Abcellera Biologics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Abcellera Biologics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Abcellera Biologics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Abcellera Biologics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.